Item Brochure
Rapid Diagnosis
• Results in 5 to 10 minutes
• Positive results may become visible sooner
Convenient Packaging
• Available in 20 test kit size, 50 and 100 test tray packs
• Additional Specimen Collection and Return Kits available
separately in convenient 10 and 40 kit sizes
• External kit controls available separately
• Room temperature storage
• 24-month shelf life from date of manufacture
Easy to Use
• Efficient collection
• Secure transport
• Convenient and sanitary dispenser
Excellent Performance
• Analytical sensitivity: 50 ng hHb/mL buffer or 50 µg
hHb/g feces
• Specificity: Specific to human hemoglobin
• Physician office laboratory agreement is 98% when
using quality control specimens
For more information on QuickVue iFOB test kits, visit our website or call your Quidel Account Manager
at 1.800.874.1517 (U.S. only), or 858.552.1100 (outside U.S.).
Quidel Corporation • Worldwide Headquarters • 10165 McKellar Court • San Diego, CA 92121 USA • quidel.com
One visit. One test. One time.
®
Colorectal cancer is the second leading cause of cancer-
related deaths in the United States for both women and
men.
1
This disease surpasses both breast and prostate cancer
in mortality, second only to lung cancer in the number of
cancer deaths.
1
Despite the fact that it is highly preventable,
1
it was estimated that 148,610 new cases of colorectal cancer
would be diagnosed and 49,960 people would die from the
disease in 2008.
2
According to the American Cancer Society
Cancer Facts and Figures 2008, “this decrease
reflects declining incidence rates and
improvements in early detection.”
Quidel’s CLIA-waived QuickVue iFOB test is
an easy to perform diagnostic tool used to
detect the presence of blood in stool speci-
mens. Blood in the stool is an indication of a
number of gastrointestinal disorders, including
colorectal cancer. Simply add six (6) drops of the buffered
specimen solution into the cassette sample well and read
the results in 5 to 10 minutes.
The QuickVue iFOB test requires only one specimen, and
because it is specific to human hemoglobin, patients are
not required to adhere to strict dietary or medication
restrictions. The result is a more patient friendly test that is
easier to complete.
3
Additionally, immunochemical FOB
tests are more analytically sensitive than traditional Guaiac
based methods.
4
The QuickVue iFOB test has the potential to
increase patient compliance and offers supe-
rior analytical performance (as compared to
Guaiac tests)
3
to positively impact both
patient care and satisfaction.
1
Cancer Research and Prevention Foundation 2005.
2
American Cancer Society, Facts and Figures, 2008.
3
OncoLog, February 2004, Volume 49, No. 2.
4
Centers for Medicare and Medicaid Services.
0016ON0905D-6_0016ON0905D-3.qxd 6/3/11 1:37 PM Page 1